Verona Pharma declares positive Phase 2 data of ensifentrine in COPD
Category: #health  By Sunil Hebbalkar  Date: 2019-08-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Verona Pharma declares positive Phase 2 data of ensifentrine in COPD
  • The company announces positive results of ensifentrine for the treatment of chronic obstructive pulmonary disease.
  • Primary and secondary lung function end-points were met successfully in the Phase 2 trial of the dry powder inhaler.

United Kingdom based-Verona Pharma plc reportedly posted positive Phase 2 results of ensifentrine for the management of chronic obstructive pulmonary disease. The sources reported that the data also included the results met by the primary and secondary lung function points during the Phase 2 trial.

As per authentic sources, the trial highlighted the results achieved for primary as well secondary endpoints. The primary points portrayed statistical and clinical dose-dependent advancement in lung function whereas the secondary points focussed upon data support of daily dosing where ensifentrine was able tolerate all the levels. 

Reportedly, the primary endpoint met a peak of FEV11  that represented improvements over baseline of 102 mL for the 150 µg2 dose, 175 mL for the 500 µg dose, 180 mL for the 1500 µg dose and so on. The secondary endpoints met major advances in FEV11  which were observed for over 12 hours for 7 days.

Jan-Anders Karlsson, Chief Executive Officer of Verona Pharma was reportedly quoted stating that the results obtained with the DPI formulation support the company’s view about ensifentrine being an effective bronchodilator for the COPD patients. The company’s Dpi formulation has been claimed to be adapted to different DPI devices used globally. It further plans to conclude the development and commercialization of the formulation with an alliance, Karlsson added.

Joseph A Boscia, Pulmonary Physician and Principle Investigator at Vitalink Research Union was quoted stating that the magnitude of response achieved by the Phase 2 trial for COPD patients is commendable. The result highlights the possibility of ensifentrine’s mechanism to help in lung function improvement and an urgent need for developed treatment.

For the records, Verona Pharma plc focuses upon the expansion and commercialization of novel medications for the treatment of respiratory diseases with major unattended medical needs.

Source credit: https://www.globenewswire.com/news-release/2019/08/05/1896642/0/en/Verona-Pharma-Reports-Positive-Phase-2-Results-with-Dry-Powder-Inhaler-Formulation-of-Ensifentrine-in-COPD.html



About Author

Sunil Hebbalkar

Email: [email protected]   

Sunil Hebbalkar

Sunil Hebbalkar develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development departm...

Read More

More News By Sunil Hebbalkar

Altaire’s veterinary ophthalmic products recalled due to QA concerns
Altaire’s veterinary ophthalmic products recalled due to QA concerns
By Sunil Hebbalkar

  • Altaire Pharmaceuticals recalls specific product/lots of ophthalmic drugs created for Dechra Veterinary Products, due to sterility concerns.
     
  • No adverse effects have been reported yet.
Biogen & Invitae introduce SMA STAT test for faster genetic testing
Biogen & Invitae introduce SMA STAT test for faster genetic testing
By Sunil Hebbalkar

Global biotechnology expert Biogen Inc. and advanced genetics leader Invitae Corporation have reportedly announced their new rapid-turnaround test for genetic testing in the diagnosis for SMA (spinal muscular atrophy)....

Target launches flagship food label with more than 2000 products
Target launches flagship food label with more than 2000 products
By Sunil Hebbalkar

US based retailer Target has reportedly announced the launch of its new private grocery brand, Good & Gather.

Starting next month, Target stores across the United States will st...